The next 12 months will deliver a number of catalysts for Nanobiotix. Readouts from a Phase I/II study with head and neck (H&N) cancer and a Phase II/III study with soft tissue sarcoma (STS) patients are due any time now. H&N cancer will be the second indication with clinical data for Nanobiotix’s lead product NBTXR3, which may have a de-risking effect on other indications in the pipeline due to the physical property of NBTXR3 to universally enhance the effect of radiotherapy. O
31 May 2016
Imminent data from two lead clinical trials
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Imminent data from two lead clinical trials
The next 12 months will deliver a number of catalysts for Nanobiotix. Readouts from a Phase I/II study with head and neck (H&N) cancer and a Phase II/III study with soft tissue sarcoma (STS) patients are due any time now. H&N cancer will be the second indication with clinical data for Nanobiotix’s lead product NBTXR3, which may have a de-risking effect on other indications in the pipeline due to the physical property of NBTXR3 to universally enhance the effect of radiotherapy. O